Latest Deep vein thrombosis Stories
For years, researchers have known that antiphospholipid antibodies (aPLs) can cause pregnancy loss and clotting, but they haven't known the true scope of the problem. Now a new study provides the first estimates of the prevalence of these antibodies in patients suffering from pregnancy loss, stroke, myocardial infarction, and deep vein thrombosis. "Based on the available data, our best estimate is that around 10 to 15% of clotting disorders are associated with autoimmune antiphospholipid...
RARITAN, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced the U.S. Food and Drug Administration (FDA) has approved XARELTO(®) (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment. To view the multimedia assets associated with this release, please click:...
GREENSBORO, N.C., Nov. 1, 2012 /PRNewswire/ -- Merz, Inc., through its aesthetics division Merz Aesthetics, Inc., the exclusive distributor of Asclera(®) (polidocanol) Injection in the U.S., today announces the beginning of the STAND AND DELIVER program. STAND AND DELIVER was originally launched in 2011 to celebrate inspirational women who are making positive contributions to their communities. After a highly successful first year, Merz Inc. has decided to continue its dedication...
CARLSBAD, Calif., Oct. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXI(Rx) in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of clots. In this study, Isis will evaluate the effectiveness of ISIS-FXI(Rx)...
The Yaz Resource Center is the Web’s largest source for information on Yaz research, side effects and legal news. Visit http://www.YazLawsuit.com Dallas, TX (PRWEB) October 25, 2012 The Federal Trade Commission announced this month that Bayer will not face any retribution over the 2008 settlement of patent litigation with Teva Pharmaceuticals, which had been suspected as a ploy to delay the release of generic Yasmin, according to an NBC News report on October 2, 2012. However, the birth...
The NuvaRing Resource Center is the Web’s largest source for information on NuvaRing side effects, research and legal news. Visit http://www.NuvaRing-Lawsuits.net Dallas, TX (PRWEB) October 25, 2012 A study by the CDC’s National Center for Health Statistics shows use of intrauterine devices such as NuvaRing are on the rise compared with condoms and traditional pills, according to a WebMD report on October 18, 2012. The study found use has grown by 700% since 1995. The news comes as...
TOKYO, Oct. 25, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has completed patient enrolment in the global Hokusai-VTE phase 3 study investigating the once-daily oral factor Xa inhibitor edoxaban for the treatment and prevention of recurrence of venous thromboembolism (VTE) in patients who have had an acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), or both.(1,2 ) Hokusai-VTE is the largest single...
U.S. Federal District Judge Rodney W. Sippel, Who is Overseeing Hundreds of NuvaRing Injury Lawsuits, Has Announced that the First Trial in the NuvaRing Litigation Will Begin on May 6, 2013. Melville, NY (PRWEB) October 24, 2012 The NuvaRing birth defect lawyers at Alonso Krangle LLP, a national law firm focused on fighting for the rights of serious personal injury victims, report that the federal litigation established for NuvaRing side effect lawsuits is moving forward. U.S. District...
Fainting after recent air travel could be a sign of pulmonary embolism (PE), a potentially fatal blockage in the lungs. Syncope or fainting is an uncommon symptom of pulmonary embolism; however, new research presented at CHEST 2012, the annual meeting of the American College of Chest Physicians (ACCP), found that fainting associated with recent air travel may be a key indicator for PE diagnosis. Fainting as a precursor to PE diagnosis was also associated with a saddle embolism, a larger and...
NuvaRing Lawsuit Alleges Merck and Other Defendants Failed to Properly Disclose the Known Safety Hazards Associated with NuvaRing, Including an Increased Risk of Pulmonary Embolism. Vandalia, Ohio (PRWEB) October 21, 2012 The national law firm of Wright & Schulte LLC has filed a NuvaRing pulmonary embolism lawsuit on behalf of an El Paso, Texas, woman who suffered a pulmonary embolism less than a year after she began using the NuvaRing birth control device. The Nuvaring side effect...
